New data hub will accelerate development and adoption of human-based New Approach Methodologies The NYU Langone-Sage ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease that is also considered an autoimmune disorder. There is no single cure for C3G, but several treatments may slow disease progression, protect ...

Results from CADENCE, the first and largest multinational prospective registry for patients with CAD/CAS, describe safety events observed in patients treated with sutimlimab, with an average treatment ...

Leaders of an effort to finance a $16.7 million renovation of Joplin’s Memorial Hall told residents during a Monday night presentation that they were hoping to receive approval of a memorandum of ...

Panelists discuss how their management approach for geographic atrophy (GA) has evolved from a “come back in a year” mentality to actively offering treatment discussions within 2 to 3 months, with ...

Complement activation in patients with AAV who are in remission may be reflective of ongoing renal scarring. Persistent complement activation during disease remission in antineutrophil cytoplasmic ...

Dianthus Therapeutics focuses on developing DNTH103, a next-gen complement inhibitor for severe autoimmune diseases, currently in trials for CIDP, gMG, and MMN. Despite promising in vitro results, ...

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...

First approved for PNH in 2007, the monoclonal antibody is now the first and only treatment for pediatric patients living with gMG. The indicated, FDA-approved use for eculizumab (Soliris; Alexion and ...